- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made).
Statutory Instruments
Prisons, England And Wales
Young Offender Institutions, England And Wales
Made
28th August 2018
Laid before Parliament
4th September 2018
Coming into force
19th October 2018
The Secretary of State makes the following Rules in exercise of the powers conferred by section 47(1) and (3A) of the Prison Act 1952(1).
1. These Rules may be cited as the Prison and Young Offender Institution (Amendment) (No. 2) Rules 2018 and come into force on 19th October 2018.
2.—(1) The Prison Rules 1999(2) are amended as follows.
(2) In rule 2(1) (interpretation)(3), for the definition of “specified drug”, substitute—
““specified drug” means any product or substance containing one or more of the chemical compounds listed in Schedule 2 to these Rules;”.”
(3) In rule 85(1) (revocations and savings), for “the Schedule,” substitute “Schedule 1”.
(4) In the Schedule (revocations), for the heading “Schedule” substitute “Schedule 1”.
(5) After Schedule 1 as renamed, insert Schedule 2 as set out in the Schedule to these Rules.
3.—(1) The Young Offender Institution Rules 2000(4) are amended as follows.
(2) In each of the following, for “the Schedule” substitute “Schedule 1”–
(a)Rule 1(b) (citation and commencement), and
(b)Rule 89(1) (revocations and savings).
(3) In rule 2(1) (interpretation)(5), for the definition of “specified drug”, substitute—
““specified drug” means any product or substance containing one or more of the chemical compounds listed in Schedule 2 to these Rules;”.”
(4) In the Schedule (revocations), for the heading “Schedule” substitute “Schedule 1”.
(5) After Schedule 1 as renamed, insert Schedule 2 as set out in the Schedule to these Rules.
Lucy Frazer
Parliamentary Under-Secretary of State
Ministry of Justice
28th August 2018
Rules 2(5) and 3(5)
Rule 2(1)
AB-PINACA (N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide);
5F-AB-PINACA (N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(5-Fluoropentyl)-1H-indazole-3-carboxamide);
AB-FUBINACA (N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide);
APICA (1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide);
5F-APICA (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide);
APINACA (1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide);
5F-APINACA (1-(5-fluoropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide);
5F-PB22 (1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid);
MDMB-CHMICA (methyl 2-{[1-(cyclohexylmethyl)-1H-indol-3-yl]formamido}-3,3-dimethylbutanoate);
PB-22 (Quinolin-8-yl-1-pentyl-1H-indole-3-carboxylate);
5F-MDMB-PINACA (Methyl-[2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate]);
AB-CHMINACA (N-[-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);
5F-AMB (Methyl 2-({[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}amino)-3-methylbutanoate);
AMB-FUBINACA (Methyl-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)-3-methylbutanoate);
Etizolam (4-(2-Chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine);
ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);
MDMB-CHMCZCA (Methyl 2-(9-(cyclohexylmethyl)-9H-carbazole-3-carboxamido)-3,3-dimethylbutanoate);
EMB-FUBINACA (Ethyl 2-[[1-[(4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3-methyl-butanoate);
5F-Cumyl-PINACA (5-(5-fluoropentyl)-2-(1-methyl-1-phenylethyl)-pyrido[4,3-b]indol-1-one);
THJ-018 (1-Naphthalenyl (1-pentyl-1H-indazol-3-yl)-methanone);
Cumyl-PEGACLONE (2-(1-Methyl-1-phenyl-ethyl)-5-pentyl-pyrido[4,3-b]indol-1-one);
Cumyl-PICA (1-Pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide);
Cumyl-THPINACA (N-(2-phenylpropan-2-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1-H-indazole-3-carboxamide;
Norfludiazepam (7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one);
Nifoxipam 5-(2-fluorophenyl)-3-hydroxy-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one;
Gabapentin - 1-(amino methyl)-cyclohexane acetic acid;
Pregabalin - (S)-3-(aminomethyl)-5-methylhexanoic acid;
Mirtazapine - 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine;
Amitriptyline - 3-(5,6-dihydrodibenzo[2,1-b:1’,2’-e][7]annulen-11-ylidene)-N,N-dimethylpropan-1-amine;
Quetiapine - (2-(2-(4-dibenzo [b,f][1,4]thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol);
Sertraline - (1S, 4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine;
Citalopram - 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;
Venlafaxine - 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol;
Carbamazepine – benzo[b][1]benzazepine-11-carboxamide;
Cetirizine - 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;
Chlorpromazine - 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine;
Fluoxetine N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine;
Haloperidol - 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one;
Lamotrigine - 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine;
Naproxen - (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid;
Nefopam - 5-methyl-1-phenyl-1,3,4,6-tetrahydro-2,5-benzoxazocine;
Olanzapine - 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine;
Paroxetine - (3S,4R)-3-[(1,3-benzodioxol-5-yloxymethyl]-4-(4-fluorophenyl)-piperidine;
Promethazine - N,N,α-Trimethyl-10H-phenothiazine-10-ethanamine;
Sildenafil - 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one;
Trazodone - 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one;
Varenicline -7,8,9,10-tetrahydro-6,10-methanol-6H-ptyrazine[2,3-h][3]benzapine;
Zopiclone - 6-(5-Chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate;
Zuclopenthixol - 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanoldihydrochloride.”
(This note is not part of the Rules)
These Rules amend the Prison Rules 1999 (S.I. 1999/728) (“the 1999 Rules”) and the Young Offender Institution Rules 2000 (S.I. 2000/3371) (“the 2000 Rules”). These Rules substitute the definition of “specified drug” in rule 2(1) of the 1999 Rules and rule 2(1) of the 2000 Rules with a revised definition in rule 2(1) and a new Schedule 2. Products or substances that fall within the revised definitions are “specified drugs” for the purposes of section 16A (testing prisoners for drugs) of the Prison Act 1952 (c. 52) (“the Act.”). The effect of section 16A of the Act is that a prison officer can require a prisoner or an inmate to provide a sample for the purpose of ascertaining whether there is a specified drug in the body of the prisoner or inmate. These Rules amend the definition of “specified drug” to include a number of additional chemical compounds. These comprise of a mixture of psychoactive substances, prescription only medicines and pharmacy medicines. The effect of the amendment is that prisoners and inmates can be tested for these additional substances.
A full impact assessment has not been produced for this instrument as no impact on the private, voluntary or public sectors is foreseen.
1952 c. 52. Section 47(1) was amended by section 6(2) of the Criminal Justice and Public Order Act 1994 (c. 33) and paragraph 3(2) of Schedule 9 to the Criminal Justice and Courts Act 2015 (c. 2). Section 47(3A) of the Prison Act 1952 was inserted by section 16(3) of the Criminal Justice and Courts Act 2015.
Rule 2 was amended by S.I. 2000/2641, 2003/3301, 2005/869, 2005/3437, 2008/597, 2009/3082, 2013/235, 2014/2169, 2016/583, 2016/945, 2018/549.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: